AU2013363876B9 - Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions - Google Patents

Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions Download PDF

Info

Publication number
AU2013363876B9
AU2013363876B9 AU2013363876A AU2013363876A AU2013363876B9 AU 2013363876 B9 AU2013363876 B9 AU 2013363876B9 AU 2013363876 A AU2013363876 A AU 2013363876A AU 2013363876 A AU2013363876 A AU 2013363876A AU 2013363876 B9 AU2013363876 B9 AU 2013363876B9
Authority
AU
Australia
Prior art keywords
levocabastine
pharmaceutical formulation
formulation
formulation according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013363876A
Other languages
English (en)
Other versions
AU2013363876A1 (en
AU2013363876B2 (en
Inventor
Diane Michele Ignar
Daren Scott LEVIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2013363876A1 publication Critical patent/AU2013363876A1/en
Application granted granted Critical
Publication of AU2013363876B2 publication Critical patent/AU2013363876B2/en
Publication of AU2013363876B9 publication Critical patent/AU2013363876B9/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AU2013363876A 2012-12-17 2013-12-13 Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions Ceased AU2013363876B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261737927P 2012-12-17 2012-12-17
US61/737,927 2012-12-17
US201361867794P 2013-08-20 2013-08-20
US61/867,794 2013-08-20
PCT/EP2013/076486 WO2014095602A1 (en) 2012-12-17 2013-12-13 Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions

Publications (3)

Publication Number Publication Date
AU2013363876A1 AU2013363876A1 (en) 2015-07-16
AU2013363876B2 AU2013363876B2 (en) 2016-12-01
AU2013363876B9 true AU2013363876B9 (en) 2016-12-15

Family

ID=49759334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013363876A Ceased AU2013363876B9 (en) 2012-12-17 2013-12-13 Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions

Country Status (11)

Country Link
US (1) US9675624B2 (cg-RX-API-DMAC10.html)
EP (1) EP2931249B1 (cg-RX-API-DMAC10.html)
JP (1) JP6294893B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150095896A (cg-RX-API-DMAC10.html)
CN (1) CN104869980A (cg-RX-API-DMAC10.html)
AU (1) AU2013363876B9 (cg-RX-API-DMAC10.html)
BR (1) BR112015014262A8 (cg-RX-API-DMAC10.html)
CA (1) CA2893654A1 (cg-RX-API-DMAC10.html)
ES (1) ES2722926T3 (cg-RX-API-DMAC10.html)
RU (1) RU2652352C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014095602A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015206486B4 (de) * 2015-04-10 2023-06-01 Adidas Ag Schuh, insbesondere Sportschuh, und Verfahren zur Herstellung desselben
USD783264S1 (en) 2015-09-15 2017-04-11 Adidas Ag Shoe
WO2019235616A1 (ja) * 2018-06-08 2019-12-12 東興薬品工業株式会社 フルチカゾンフランカルボン酸エステル点鼻組成物
JP7021301B2 (ja) * 2019-07-23 2022-02-16 ニコックス アフサァルミィクス、 インコーポレイテッド 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
RU2736082C1 (ru) * 2019-12-02 2020-11-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Фармацевтическая композиция противоаллергического и противовоспалительного действия для интраназального применения
AU2021291684A1 (en) * 2020-06-15 2022-12-08 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
AR068988A1 (es) * 2007-10-16 2009-12-23 Glaxo Group Ltd Composiciones farmaceuticas
CN101757625A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 环糊精包合皮质激素和h1受体拮抗剂的鼻用药物组合物

Also Published As

Publication number Publication date
JP6294893B2 (ja) 2018-03-14
US20150297614A1 (en) 2015-10-22
RU2015121039A (ru) 2017-01-23
EP2931249A1 (en) 2015-10-21
AU2013363876A1 (en) 2015-07-16
WO2014095602A1 (en) 2014-06-26
CA2893654A1 (en) 2014-06-26
US9675624B2 (en) 2017-06-13
BR112015014262A8 (pt) 2019-10-08
BR112015014262A2 (pt) 2017-07-11
ES2722926T3 (es) 2019-08-20
RU2652352C2 (ru) 2018-04-25
AU2013363876B2 (en) 2016-12-01
JP2016502991A (ja) 2016-02-01
EP2931249B1 (en) 2019-01-16
KR20150095896A (ko) 2015-08-21
CN104869980A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
AU2012204557B2 (en) Bepotastine compositions
AU2013363876B2 (en) Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
KR101312311B1 (ko) 약학적 코 제형물 및 이의 이용 방법
JP5785360B2 (ja) 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤
US10016443B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US20240156840A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
EP3755375B1 (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
RU2798030C2 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина
US10653661B2 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
HK40033829B (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
HK40033829A (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
EA047266B1 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина
NZ616149B2 (en) Nasal Pharmaceutical Formulation Comprising Fluticasone

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired